Published :
Tables : 55
Figures : 49
Category : Healthcare
No. of Pages : 240
Report Code : HC-U3230
Sepsis Diagnostics Market is poised to value over CAGR of over 8.8% during the forecast period 2022 to 2028. The increasing geriatric population across the world, regulated governmental initiatives for creating awareness regarding sepsis are some of the primary reasons for the remarkable proliferation of the sepsis diagnostics market. According to a study conducted by the WHO, the number of patients diagnosed with sepsis were over 30 million in 2018, leading to over 5 million deaths every year. Such a high prevalence of sepsis is predicted to increase the requirement for diagnostic solutions, thus augmenting the market growth. FutureWise Market Research has instantiated a report that provides an intricate analysis of Sepsis Diagnostics Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market. According to the research study conducted by FutureWise research analysts, the market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical. Major players included in the Sepsis Diagnostics Market: Biomérieux T2 Biosystems Luminex Becton,Dickinson,And Company (Bd) Roche Diagnostics (A Subsidiary Of F. Hoffmann-La Roche Ltd.) Danaher Thermo Fisher Scientific Bruker Abbott Immunexpress Response Biomedical Axis-Shield Diagnostics Cytosorbents Mitsubishi Chemical Europe Ekf Diagnostics (Note: The list of the major players will be updated with the latest market scenario and trends) Sepsis Diagnostics Market Segmentation: By Technology • Blood Culture • Immunoassays • Molecular Diagnostics o PCR o Peptide Nucleic Acid-Fluorescent In Situ Hybridization o Microarrays o Syndromic Panel-Based Testing • Flow Cytometry • Microfluidics • Biomarkers By Product • Blood Culture Media • Assays & Reagents • Instruments • Software By Pathogen • Bacterial Sepsis o Gram-positive bacteria o Gram-negative bacteria • Fungal Sepsis • Other Pathogens By Method • Conventional Diagnostics • Automated Diagnostics By Test Type • Laboratory Tests • Point-of-care Tests By End User • Hospitals • Pathology & Reference Laboratories • Research Laboratories & Academic Institutes By Region • North America • Europe • Asia-Pacific • Latin America • Middle East and Africa Competitive Landscape: Tier 1 players- established companies in the market with a major market share Tier 2 players Emerging players which are growing rapidly New Entrants FutureWise Key Takeaways: Growth prospects SWOT analysis Key trends Key data-points affecting market growth Objectives of the Study: To provide with an exhaustive analysis on the Sepsis Diagnostics Market By Technology, By Product, By Pathogen, By Method, By Test Type, By End User and By Region. To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) To evaluate and forecast micro-markets and the overall market To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa. To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions Flexible Delivery Model: We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement The customization Mobility Care offered are free of charge with purchase of any license of the report You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
The increasing geriatric population across the world, regulated governmental initiatives for creating awareness regarding sepsis are some of the primary reasons for the remarkable proliferation of the sepsis diagnostics market. According to a study conducted by the WHO, the number of patients diagnosed with sepsis were over 30 million in 2018, leading to over 5 million deaths every year. Such a high prevalence of sepsis is predicted to increase the requirement for diagnostic solutions, thus augmenting the market growth.
FutureWise Market Research has instantiated a report that provides an intricate analysis of Sepsis Diagnostics Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.
According to the research study conducted by FutureWise research analysts, the market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.
Major players included in the Sepsis Diagnostics Market:
(Note: The list of the major players will be updated with the latest market scenario and trends)
Sepsis Diagnostics Market Segmentation:
By Technology
• Blood Culture • Immunoassays • Molecular Diagnostics o PCR o Peptide Nucleic Acid-Fluorescent In Situ Hybridization o Microarrays o Syndromic Panel-Based Testing • Flow Cytometry • Microfluidics • Biomarkers
By Product
• Blood Culture Media • Assays & Reagents • Instruments • Software
By Pathogen
• Bacterial Sepsis o Gram-positive bacteria o Gram-negative bacteria • Fungal Sepsis • Other Pathogens
By Method
• Conventional Diagnostics • Automated Diagnostics
By Test Type
• Laboratory Tests • Point-of-care Tests
By End User
• Hospitals • Pathology & Reference Laboratories • Research Laboratories & Academic Institutes
By Region
• North America • Europe • Asia-Pacific • Latin America • Middle East and Africa
Competitive Landscape:
FutureWise Key Takeaways:
Objectives of the Study:
Flexible Delivery Model:
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders 2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study 3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights 4. Sepsis Diagnostics Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Sepsis Diagnostics Market Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Sepsis Diagnostics Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Sepsis Diagnostics Market, By Technology Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. Blood Culture 7.2. Immunoassays 7.3. Molecular Diagnostics 7.3.1. PCR 7.3.2. Peptide Nucleic Acid-Fluorescent In Situ Hybridization 7.3.3. Microarrays 7.3.4. Syndromic Panel-Based Testing 7.4. Flow Cytometry 7.5. Microfluidics 7.6. Biomarkers 8. Sepsis Diagnostics Market, By Product Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Blood Culture Media 8.2. Assays & Reagents 8.3. Instruments 8.4. Software 9. Sepsis Diagnostics Market, By Pathogen Historical Analysis and Forecast 2022-2028 (USD Million) 9.1. Bacterial Sepsis 9.1.1. Gram-positive bacteria 9.1.2. Gram-negative bacteria 9.2. Fungal Sepsis 9.3. Other Pathogens 10. Sepsis Diagnostics Market, By Method Historical Analysis and Forecast 2022-2028 (USD Million) 10.1. Conventional Diagnostics 10.2. Automated Diagnostics 11. Sepsis Diagnostics Market, By Test Type Historical Analysis and Forecast 2022-2028 (USD Million) 11.1. Laboratory Tests 11.2. Point-of-care Tests 12. Sepsis Diagnostics Market, By End User Historical Analysis and Forecast 2022-2028 (USD Million) 12.1. Hospitals 12.2. Pathology & Reference Laboratories 12.3. Research Laboratories & Academic Institutes 13. North America Sepsis Diagnostics Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. U.S.A 13.2.2. Canada 13.2.3. Mexico 13.3. Market Size (USD Million) Forecast for North America 2022-2028 14. Latin America Sepsis Diagnostics Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 14.2.1. Brazil 14.2.2. Venezuela 14.2.3. Argentina 14.2.4. Rest of Latin America 14.3. Market Size (USD Million) Forecast for Latin America 2022-2028 15. Europe Sepsis Diagnostics Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 15.1. Introduction 15.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 15.2.1. Germany 15.2.2. U.K 15.2.3. France 15.2.4. Italy 15.2.5. Spain 15.2.6. Russia 15.2.7. Poland 15.2.8. Rest of Europe 15.3. Market Size (USD Million) Forecast for Europe 2022-2028 16. Asia Pacific Sepsis Diagnostics Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 16.1. Introduction 16.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 16.2.1. Japan 16.2.2. China 16.2.3. India 16.2.4. Australia and New Zealand 16.2.5. ASEAN 16.2.6. Rest of Asia Pacific 16.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028 17. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 17.1. Introduction 17.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 17.2.1. GCC 17.2.2. Israel 17.2.3. South Africa 17.2.4. Rest of MEA 17.3. Market Size (USD Million) Forecast for MEA 2022-2028 18. Market Share Analysis and Competitive Landscape 18.1. Global Landscape - Key Players, Revenue and Presence 18.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 18.3. Global Emerging Companies 18.4. North America - Market Share Analysis and Key Regional Players 18.5. Europe - Market Share Analysis and Key Regional Players 18.6. Asia Pacific - Market Share Analysis and Key Regional Players 18.7. Global Key Player - Growth Matrix 19. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts) 19.1. Biomérieux 19.1.1. Company Overview 19.1.2. Product Portfolio 19.1.3. SWOT Analysis 19.1.4. Financial Overview 19.1.5. Strategic Overview 19.2. T2 Biosystems 19.2.1. Company Overview 19.2.2. Product Portfolio 19.2.3. SWOT Analysis 19.2.4. Financial Overview 19.2.5. Strategic Overview 19.3. Luminex 19.3.1. Company Overview 19.3.2. Product Portfolio 19.3.3. SWOT Analysis 19.3.4. Financial Overview 19.3.5. Strategic Overview 19.4. Becton,Dickinson and Company (Bd) 19.4.1. Company Overview 19.4.2. Product Portfolio 19.4.3. SWOT Analysis 19.4.4. Financial Overview 19.4.5. Strategic Overview 19.5. Roche Diagnostics (A Subsidiary Of F. Hoffmann-La Roche Ltd.) 19.5.1. Company Overview 19.5.2. Product Portfolio 19.5.3. SWOT Analysis 19.5.4. Financial Overview 19.5.5. Strategic Overview 19.6. Danaher 19.6.1. Company Overview 19.6.2. Product Portfolio 19.6.3. SWOT Analysis 19.6.4. Financial Overview 19.6.5. Strategic Overview 19.7. Thermo Fisher Scientific 19.7.1. Company Overview 19.7.2. Product Portfolio 19.7.3. SWOT Analysis 19.7.4. Financial Overview 19.7.5. Strategic Overview 19.8. Bruker 19.8.1. Company Overview 19.8.2. Product Portfolio 19.8.3. SWOT Analysis 19.8.4. Financial Overview 19.8.5. Strategic Overview 19.9. Abbott 19.9.1. Company Overview 19.9.2. Product Portfolio 19.9.3. SWOT Analysis 19.9.4. Financial Overview 19.9.5. Strategic Overview 19.10.Immunexpress 19.10.1. Company Overview 19.10.2. Product Portfolio 19.10.3. SWOT Analysis 19.10.4. Financial Overview 19.10.5. Strategic Overview 19.11.Response Biomedical 19.11.1. Company Overview 19.11.2. Product Portfolio 19.11.3. SWOT Analysis 19.11.4. Financial Overview 19.11.5. Strategic Overview 19.12.Axis-Shield Diagnostics 19.12.1. Company Overview 19.12.2. Product Portfolio 19.12.3. SWOT Analysis 19.12.4. Financial Overview 19.12.5. Strategic Overview 19.13.Cytosorbents 19.13.1. Company Overview 19.13.2. Product Portfolio 19.13.3. SWOT Analysis 19.13.4. Financial Overview 19.13.5. Strategic Overview 19.14.Mitsubishi Chemical Europe 19.14.1. Company Overview 19.14.2. Product Portfolio 19.14.3. SWOT Analysis 19.14.4. Financial Overview 19.14.5. Strategic Overview 19.15.Ekf Diagnostics 19.15.1. Company Overview 19.15.2. Product Portfolio 19.15.3. SWOT Analysis 19.15.4. Financial Overview 19.15.5. Strategic Overview 20. Pre and Post COVID-19 Impact 20.1. Positive influence on the healthcare industry 20.2. The financial disruption of the manufacturing sector 20.3. Impact of COVID-19 on emerging companies 20.4. Significant mandates in the healthcare regulations initiated by administrations 20.5. The overall economic slowdown of the developing and developed nations 21. FutureWise SME Key Takeaway Points for Client
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders
2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study
3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights
4. Sepsis Diagnostics Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances
5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Sepsis Diagnostics Market Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework
6. Sepsis Diagnostics Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies
7. Sepsis Diagnostics Market, By Technology Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. Blood Culture 7.2. Immunoassays 7.3. Molecular Diagnostics 7.3.1. PCR 7.3.2. Peptide Nucleic Acid-Fluorescent In Situ Hybridization 7.3.3. Microarrays 7.3.4. Syndromic Panel-Based Testing 7.4. Flow Cytometry 7.5. Microfluidics 7.6. Biomarkers
8. Sepsis Diagnostics Market, By Product Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Blood Culture Media 8.2. Assays & Reagents 8.3. Instruments 8.4. Software
9. Sepsis Diagnostics Market, By Pathogen Historical Analysis and Forecast 2022-2028 (USD Million) 9.1. Bacterial Sepsis 9.1.1. Gram-positive bacteria 9.1.2. Gram-negative bacteria 9.2. Fungal Sepsis 9.3. Other Pathogens
10. Sepsis Diagnostics Market, By Method Historical Analysis and Forecast 2022-2028 (USD Million) 10.1. Conventional Diagnostics 10.2. Automated Diagnostics 11. Sepsis Diagnostics Market, By Test Type Historical Analysis and Forecast 2022-2028 (USD Million) 11.1. Laboratory Tests 11.2. Point-of-care Tests
12. Sepsis Diagnostics Market, By End User Historical Analysis and Forecast 2022-2028 (USD Million) 12.1. Hospitals 12.2. Pathology & Reference Laboratories 12.3. Research Laboratories & Academic Institutes
13. North America Sepsis Diagnostics Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. U.S.A 13.2.2. Canada 13.2.3. Mexico 13.3. Market Size (USD Million) Forecast for North America 2022-2028
14. Latin America Sepsis Diagnostics Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 14.2.1. Brazil 14.2.2. Venezuela 14.2.3. Argentina 14.2.4. Rest of Latin America 14.3. Market Size (USD Million) Forecast for Latin America 2022-2028
15. Europe Sepsis Diagnostics Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 15.1. Introduction 15.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 15.2.1. Germany 15.2.2. U.K 15.2.3. France 15.2.4. Italy 15.2.5. Spain 15.2.6. Russia 15.2.7. Poland 15.2.8. Rest of Europe 15.3. Market Size (USD Million) Forecast for Europe 2022-2028
16. Asia Pacific Sepsis Diagnostics Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 16.1. Introduction 16.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 16.2.1. Japan 16.2.2. China 16.2.3. India 16.2.4. Australia and New Zealand 16.2.5. ASEAN 16.2.6. Rest of Asia Pacific 16.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028
17. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 17.1. Introduction 17.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 17.2.1. GCC 17.2.2. Israel 17.2.3. South Africa 17.2.4. Rest of MEA 17.3. Market Size (USD Million) Forecast for MEA 2022-2028
18. Market Share Analysis and Competitive Landscape 18.1. Global Landscape - Key Players, Revenue and Presence 18.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 18.3. Global Emerging Companies 18.4. North America - Market Share Analysis and Key Regional Players 18.5. Europe - Market Share Analysis and Key Regional Players 18.6. Asia Pacific - Market Share Analysis and Key Regional Players 18.7. Global Key Player - Growth Matrix
19. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts) 19.1. Biomérieux 19.1.1. Company Overview 19.1.2. Product Portfolio 19.1.3. SWOT Analysis 19.1.4. Financial Overview 19.1.5. Strategic Overview 19.2. T2 Biosystems 19.2.1. Company Overview 19.2.2. Product Portfolio 19.2.3. SWOT Analysis 19.2.4. Financial Overview 19.2.5. Strategic Overview 19.3. Luminex 19.3.1. Company Overview 19.3.2. Product Portfolio 19.3.3. SWOT Analysis 19.3.4. Financial Overview 19.3.5. Strategic Overview 19.4. Becton,Dickinson and Company (Bd) 19.4.1. Company Overview 19.4.2. Product Portfolio 19.4.3. SWOT Analysis 19.4.4. Financial Overview 19.4.5. Strategic Overview 19.5. Roche Diagnostics (A Subsidiary Of F. Hoffmann-La Roche Ltd.) 19.5.1. Company Overview 19.5.2. Product Portfolio 19.5.3. SWOT Analysis 19.5.4. Financial Overview 19.5.5. Strategic Overview 19.6. Danaher 19.6.1. Company Overview 19.6.2. Product Portfolio 19.6.3. SWOT Analysis 19.6.4. Financial Overview 19.6.5. Strategic Overview 19.7. Thermo Fisher Scientific 19.7.1. Company Overview 19.7.2. Product Portfolio 19.7.3. SWOT Analysis 19.7.4. Financial Overview 19.7.5. Strategic Overview 19.8. Bruker 19.8.1. Company Overview 19.8.2. Product Portfolio 19.8.3. SWOT Analysis 19.8.4. Financial Overview 19.8.5. Strategic Overview 19.9. Abbott 19.9.1. Company Overview 19.9.2. Product Portfolio 19.9.3. SWOT Analysis 19.9.4. Financial Overview 19.9.5. Strategic Overview 19.10.Immunexpress 19.10.1. Company Overview 19.10.2. Product Portfolio 19.10.3. SWOT Analysis 19.10.4. Financial Overview 19.10.5. Strategic Overview 19.11.Response Biomedical 19.11.1. Company Overview 19.11.2. Product Portfolio 19.11.3. SWOT Analysis 19.11.4. Financial Overview 19.11.5. Strategic Overview 19.12.Axis-Shield Diagnostics 19.12.1. Company Overview 19.12.2. Product Portfolio 19.12.3. SWOT Analysis 19.12.4. Financial Overview 19.12.5. Strategic Overview 19.13.Cytosorbents 19.13.1. Company Overview 19.13.2. Product Portfolio 19.13.3. SWOT Analysis 19.13.4. Financial Overview 19.13.5. Strategic Overview 19.14.Mitsubishi Chemical Europe 19.14.1. Company Overview 19.14.2. Product Portfolio 19.14.3. SWOT Analysis 19.14.4. Financial Overview 19.14.5. Strategic Overview 19.15.Ekf Diagnostics 19.15.1. Company Overview 19.15.2. Product Portfolio 19.15.3. SWOT Analysis 19.15.4. Financial Overview 19.15.5. Strategic Overview
20. Pre and Post COVID-19 Impact 20.1. Positive influence on the healthcare industry 20.2. The financial disruption of the manufacturing sector 20.3. Impact of COVID-19 on emerging companies 20.4. Significant mandates in the healthcare regulations initiated by administrations 20.5. The overall economic slowdown of the developing and developed nations
21. FutureWise SME Key Takeaway Points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics